Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

June 22, 2020 Issue

June 22, 2020 Cover

Volume 98, Issue 24

With the help of outsourcing partners, the small biotech firm Nabriva brought lefamulin to patients by itself. Now it needs to make a profit in the tough-to-crack antibiotic business

Full Article
Volume 98 | Issue 24

All Issues

Quote of the Week

“Every time there is a major incident, we demonstrate our value to the American public.”

Kristen Kulinowski, former member, US Chemical Safety and Hazard Investigation Board

Drug Development

One molecule’s journey from discovery to market

With the help of outsourcing partners, the small biotech firm Nabriva brought lefamulin to patients by itself. Now it needs to make a profit in the tough-to-crack antibiotic business

  • Former US Chemical Safety Board member Kristen Kulinowski reflects on her term

    She is ‘bullish’ on the board’s future despite history of turmoil

  • What you need to know to get back to the lab amid the COVID-19 pandemic

    Managing expectations will be key, says Jen Heemstra

ADVERTISEMENT
image name
Infectious disease

Dexamethasone appears to help severe cases of COVID-19

The inexpensive, well-studied steroid could give doctors another tool in the coronavirus pandemic

ADVERTISEMENT
ADVERTISEMENT